Search results
Showing 331 to 345 of 664 results for kidney or kidneys or renal
Cannabidiol for treating seizures caused by tuberous sclerosis complex (TA873)
Evidence-based recommendations on cannabidiol (Epidyolex) for treating seizures caused by tuberous sclerosis complex.
Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism (TA354)
Evidence-based recommendations on edoxaban (Lixiana) for treating deep vein thrombosis and pulmonary embolism in adults and preventing them happening again.
NICE has developed a medtech innovation briefing (MIB) on PIUR tUS for abdominal aortic aneurysm surveillance and endovascular aneurysm repair endoleak detection .
Summary of the evidence on avanafil for treating erectile dysfunction to inform local NHS planning and decision-making
RenalSense Clarity RMS for acute kidney injury MT601 (MIB256)
Topic prioritisation
Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism (TA287)
Evidence-based recommendations on rivaroxaban (Xarelto) for treating pulmonary embolism and for preventing a further deep vein thrombosis or pulmonary embolism in adults.
Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemia (TA891)
Evidence-based recommendations on ibrutinib (Imbruvica) with venetoclax (Venclyxto) for untreated chronic lymphocytic leukaemia in adults.
Pazopanib for the second line treatment of advanced and/or metastatic renal cell carcinoma [ID70]
Discontinued Reference number: GID-TAG398
NICE has developed a medtech innovation briefing (MIB) on The Insides System for managing intestinal failure .
Veverimer for treating metabolic acidosis in chronic kidney disease [ID3832]
Topic prioritisation
Antimicrobial prescribing: imipenem with cilastatin and relebactam (ES30)
Summary of the evidence on antimicrobial prescribing: imipenem with cilastatin and relebactam
Summary of the evidence on cangrelor for coronary revascularisation to inform local NHS planning and decision-making
This guideline sets out an antimicrobial prescribing strategy for human and animal bites (excluding insect bites) in adults, young people and children aged 72 hours and over. It aims to optimise antibiotic use and reduce antibiotic resistance.
Fluorouracil chemotherapy: The My5‑FU assay for guiding dose adjustment (HTG360)
Evidence-based recommendations on the My5-FU assay for measuring levels of 5-flurouracil (5-FU) in patients having chemotherapy, to help guide changes to the dose of 5-FU.
clinical and cost effectiveness of having keyworkers present in the context of renal replacement therapy (RRT)? Any explanatory notes(if...